Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Airway

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,312 result(s) found for: Airway. Displaying page 3 of 66.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-002356-20 Sponsor Protocol Number: CLI-05993BA1-08 Start Date*: 2021-05-04
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Open label, prospective study to evaluate the effect of step-up from non-extrafine ICS/LABA DPI to extra fine triple therapy with CHF5993 DPI on airway geometry and lung ventilation using FRI in su...
    Medical condition: COPD (Chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-005819-10 Sponsor Protocol Number: KKS-95 Start Date*: 2007-12-07
    Sponsor Name:Philipps-University Marburg
    Full Title: Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation -TIBROMUC-
    Medical condition: Anticholinergic bronchodilators, such as ipratropium bromide, may be used in combination with beta adrenergic agonists as SAlbutamol to produce bronchodilation in excess of that achieved by either ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005389-39 Sponsor Protocol Number: D2340C00011 Start Date*: 2012-03-12
    Sponsor Name:ASTRAZENECA
    Full Title: A phase-II, double-blind, placebo-controlled, randomised, parallelgroup, multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice d...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-004461-13 Sponsor Protocol Number: CQVA149A2325 Start Date*: 2016-04-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003647-36 Sponsor Protocol Number: 1222.11 Start Date*: 2009-02-24
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] an...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005087-26 Sponsor Protocol Number: 1237.4 Start Date*: 2008-06-25
    Sponsor Name:Boehringer Ingelheim GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003704-67 Sponsor Protocol Number: 1222.12 Start Date*: 2009-02-24
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] an...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004680-21 Sponsor Protocol Number: CQVA149ADE05 Start Date*: 2015-04-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blinded, single-center, placebo controlled, cross-over study to assess the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) on cardiac function in patients with...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001530-28 Sponsor Protocol Number: CQBW251X2201 Start Date*: 2016-05-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics and efficacy of multiple doses of QBW251 in patients with COPD.
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002264-24 Sponsor Protocol Number: 1237.26 Start Date*: 2013-11-14
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001704-10 Sponsor Protocol Number: D5980C00019 Start Date*: 2018-12-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Two Treatment, Two Period, Chronic dosing (4 weeks), Crossover, Multi-center Pilot study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate and G...
    Medical condition: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010669-22 Sponsor Protocol Number: 1237.6 Start Date*: 2011-09-19
    Sponsor Name: [...]
    1.
    2. Boehringer Ingelheim Norway KS
    Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium plus olodaterol fixed dose combination (2.5 μg / ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) ES (Completed) SK (Completed) BE (Completed) DE (Completed) HU (Completed) IE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008192-34 Sponsor Protocol Number: ERD-01-08/EP Start Date*: 2009-08-13
    Sponsor Name:EDMOND PHARMA S.R.L.
    Full Title: THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomized, double-blind, placebo-controlled, parallel group, multicenter...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10029978 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) FR (Completed) DK (Completed) SK (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-001933-84 Sponsor Protocol Number: 1222.13 Start Date*: 2008-11-18
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004086-33 Sponsor Protocol Number: 205.334 Start Date*: 2007-07-25
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on sta...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) AT (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016251-21 Sponsor Protocol Number: 205.458 Start Date*: 2010-10-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003103-39 Sponsor Protocol Number: AR003 Start Date*: 2007-04-19
    Sponsor Name:University of Glasgow & Greater Glasgow Health Board
    Full Title: Effect of statins on asthma control and airway inflammation in smokers with asthma
    Medical condition: Chronic Asthma (smokers),COPD.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003937-42 Sponsor Protocol Number: BY217/M2-124 Start Date*: 2005-06-16
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004684-22 Sponsor Protocol Number: CQAB149B2318 Start Date*: 2008-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory, double-blind, randomized, placebocontrolled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate (300 mcg) on dynamic and static lung hyperinflati...
    Medical condition: COPD (Chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013686-26 Sponsor Protocol Number: CQAB149BDE01 Start Date*: 2009-10-16
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate ...
    Medical condition: moderate chonic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 08:17:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA